These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22499233)

  • 1. Ivacaftor (Kalydeco) for cystic fibrosis.
    Med Lett Drugs Ther; 2012 Apr; 54(1388):29-30. PubMed ID: 22499233
    [No Abstract]   [Full Text] [Related]  

  • 2. Ivacaftor imaging response in cystic fibrosis.
    Hoare S; McEvoy S; McCarthy CJ; Kilcoyne A; Brady D; Gibney B; Gallagher CG; McKone EF; Dodd JD
    Am J Respir Crit Care Med; 2014 Feb; 189(4):484. PubMed ID: 24528318
    [No Abstract]   [Full Text] [Related]  

  • 3. Ivacaftor in a G551D homozygote with cystic fibrosis.
    Harrison MJ; Murphy DM; Plant BJ
    N Engl J Med; 2013 Sep; 369(13):1280-2. PubMed ID: 24066763
    [No Abstract]   [Full Text] [Related]  

  • 4. Ivacaftor for patients with cystic fibrosis.
    Wainwright CE
    Expert Rev Respir Med; 2014 Oct; 8(5):533-8. PubMed ID: 25148205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resolution of Intestinal Histopathology Changes in Cystic Fibrosis after Treatment with Ivacaftor.
    Safe M; Gifford AJ; Jaffe A; Ooi CY
    Ann Am Thorac Soc; 2016 Feb; 13(2):297-8. PubMed ID: 26848606
    [No Abstract]   [Full Text] [Related]  

  • 6. Improvement of hepatic steatosis in cystic fibrosis with ivacaftor therapy.
    Hayes D; Warren PS; McCoy KS; Sheikh SI
    J Pediatr Gastroenterol Nutr; 2015 May; 60(5):578-9. PubMed ID: 25688481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystic fibrosis, ivacaftor, and the Arg117His-CFTR mutation.
    Accurso FJ
    Lancet Respir Med; 2015 Jul; 3(7):498-9. PubMed ID: 26170070
    [No Abstract]   [Full Text] [Related]  

  • 8. Resolution of cystic fibrosis-related diabetes with ivacaftor therapy.
    Hayes D; McCoy KS; Sheikh SI
    Am J Respir Crit Care Med; 2014 Sep; 190(5):590-1. PubMed ID: 25171312
    [No Abstract]   [Full Text] [Related]  

  • 9. [Combined administration of lumacaftor and ivacaftor as a causal therapeutic approach].
    Desch M
    Med Monatsschr Pharm; 2016 Jan; 39(1):42-4. PubMed ID: 26975180
    [No Abstract]   [Full Text] [Related]  

  • 10. Improvement of sinus disease in cystic fibrosis with ivacaftor therapy.
    Hayes D; McCoy KS; Sheikh SI
    Am J Respir Crit Care Med; 2014 Aug; 190(4):468. PubMed ID: 25127305
    [No Abstract]   [Full Text] [Related]  

  • 11. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688
    [No Abstract]   [Full Text] [Related]  

  • 12. Foundation receives $3.3-billion windfall for Kalydeco.
    Senior M
    Nat Biotechnol; 2015 Jan; 33(1):8-9. PubMed ID: 25574617
    [No Abstract]   [Full Text] [Related]  

  • 13. A young Hispanic with c.1646G>A mutation exhibits severe cystic fibrosis lung disease: is ivacaftor an option for therapy?
    Yarlagadda S; Zhang W; Penmatsa H; Ren A; Arora K; Naren AP; Khan FA; Donnellan CA; Srinivasan S; Stokes DC; Kappes JC
    Am J Respir Crit Care Med; 2012 Oct; 186(7):694-6. PubMed ID: 23027855
    [No Abstract]   [Full Text] [Related]  

  • 14. CT imaging of pediatric patients with cystic fibrosis on ivacaftor therapy.
    Hayes D; Long FR; McCoy KS; Sheikh SI
    Lung; 2014 Oct; 192(5):823-4. PubMed ID: 25099273
    [No Abstract]   [Full Text] [Related]  

  • 15. Changes in Lung Clearance Index in Preschool-aged Patients with Cystic Fibrosis Treated with Ivacaftor (GOAL): A Clinical Trial.
    Ratjen F; Klingel M; Black P; Powers MR; Grasemann H; Solomon M; Sagel SD; Donaldson SH; Rowe SM; Rosenfeld M
    Am J Respir Crit Care Med; 2018 Aug; 198(4):526-528. PubMed ID: 29614238
    [No Abstract]   [Full Text] [Related]  

  • 16. Immeasurable Time Bias In Exposure to Ivacaftor.
    Sarayani A; Winterstein AG
    Health Aff (Millwood); 2019 Feb; 38(2):328. PubMed ID: 30715971
    [No Abstract]   [Full Text] [Related]  

  • 17. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.
    Heltshe SL; Mayer-Hamblett N; Burns JL; Khan U; Baines A; Ramsey BW; Rowe SM;
    Clin Infect Dis; 2015 Mar; 60(5):703-12. PubMed ID: 25425629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ivacaftor, vismodegib, and ingenol mebutate.
    Hussar DA; Eckel SP
    J Am Pharm Assoc (2003); 2012; 52(3):418-22. PubMed ID: 22618984
    [No Abstract]   [Full Text] [Related]  

  • 20. Sweat chloride is not a useful marker of clinical response to Ivacaftor.
    Barry PJ; Jones AM; Webb AK; Horsley AR
    Thorax; 2014 Jun; 69(6):586-7. PubMed ID: 24258833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.